Drug Topics

NOVEMBER 2, 2022

It’s too late for retail chain pharmacies to engage in the preventive maintenance that would have spared them the worst of the Great Resignation.

187

187

Pharmacy Times

NOVEMBER 2, 2022

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

132

132

Drug Topics

NOVEMBER 2, 2022

Recently published research reveals an important benefit for middle-aged and older adults: a reduction in ischemic stroke risk.

201

201

Pharmacy Times

NOVEMBER 2, 2022

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke.

132

132

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

NOVEMBER 2, 2022

Digital therapeutics are rapidly coming into the foreground to treat a variety of conditions. Ben Hargreaves discovers how chronic pain could be a key area for digital therapeutics, as they offer non-addictive and effective relief from the condition. The struggle to manage pain for individuals has been one that goes back a long way in history, with one of the earliest recorded medical prescriptions being for opium.

FDA 135

FDA Dosage 135

Pharmacy Times

NOVEMBER 2, 2022

Pre-planned safety reviews performed for the duration of the study found that the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

Vaccines 123

Vaccines 123

STAT

NOVEMBER 2, 2022

Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on two CRISPR-based treatments before the end of the year — data the troubled biotech hopes will ease investor doubts about its gene-editing technology. Other CRISPR companies command multibillion-dollar valuations, but Editas, one of the originals, trades below its IPO price after years of management upheaval and clinical delay.

130

130

Drug Store News

NOVEMBER 2, 2022

In an SEC filing on Wednesday CVS said that it is “determined that its LTC business was no longer a strategic asset, and during the third quarter of 2022 committed to a plan to sell.

119

119

Pharmacy Times

NOVEMBER 2, 2022

Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor specifically indicated to treat HBV in adults with compensated liver disease.

FDA 120

FDA 120

Pharmaceutical Technology

NOVEMBER 2, 2022

Pfizer has reported a 6% decline in revenue to $22.6bn in the third quarter (Q3) of 2022 as against $24bn in the same quarter last year. In the quarter, revenues rose 2% operationally on omitting contributions from Covid-19 therapies, Paxlovid and Comirnaty. Reduction in revenues from Comirnaty outside the US and reduced revenues for some Comirnaty-linked manufacturing works carried out on behalf of BioNTech, Xeljanz and Sutent worldwide were the key drivers that contributed to the revenue dec

116

116

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

NOVEMBER 2, 2022

Investing in adequate education and training of new employees up front can save a considerable amount of time and money on the back end.

123

123

STAT

NOVEMBER 2, 2022

Dani Yuengling, a 35-year-old South Carolinian, had a family history of fatal breast cancer. So when she noticed a lump in one of her breasts, she immediately made an appointment to see her doctor. Though her biopsy was covered by insurance, she still had to pay $5,169 out of her own pocket. If she hadn’t used her insurance, Yuengling would have saved $3,000.

Insurance 114

Insurance Hospitals 114

Pharmacy Times

NOVEMBER 2, 2022

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.

Immunization 117

Immunization 117

pharmaphorum

NOVEMBER 2, 2022

One of the highlights of Eli Lilly’s third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been described as “viral” take-up by the drugmaker. Lilly’s head of diabetes, Mike Mason, said on the company’s results call that the rollout of Mounjaro (tirzepatide) was “really unprecedented” for a new diabetes therapy in the US, and had been driven by “tremendous

FDA 105

FDA 105

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

NOVEMBER 2, 2022

Dr Vinokurov illustrates the evolving role of pharmacists in HR+/HER2- breast cancer treatment.

145

145

STAT

NOVEMBER 2, 2022

The federal government is officially reducing Medicare payments to physicians next year by 4.5%, but doctors and their lobbyists are ready to blitz Congress over the next two months to convince lawmakers that those cuts should be averted — again. Medicare signaled these cuts were coming over the summer and finalized them this week in a new regulation.

Hospitals 107

Hospitals 107

Pharmacy Times

NOVEMBER 2, 2022

Wassim McHayleh, MD, MBA, FACP, and Alisa Vinokurov, PharmD, discuss HR+/HER2- breast cancer.

139

139

STAT

NOVEMBER 2, 2022

A blockbuster weight-loss medicine led to dramatic effects for adolescents diagnosed with obesity, a result that will likely widen the use of an in-demand drug — and fan a debate over whether someone’s body weight should be treated as a disease. The drug, a weekly injection called semaglutide, led to a 17% reduction in body mass index compared to placebo in a study of about 200 people between the ages of 12 and 18.

103

103

Drug Topics

NOVEMBER 2, 2022

Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality.

FDA 98

FDA 98

STAT

NOVEMBER 2, 2022

The hype around psychedelic therapy has been put to the test, with the publication Wednesday of the largest-ever study of psilocybin to treat depression. The Phase 2 trial found that the drug was effective — it reduced or eliminated symptoms in the short term in more than one-third of patients who took the highest dose — but not as dazzlingly powerful as earlier smaller studies had suggested.

103

103

Drug Store News

NOVEMBER 2, 2022

According to a survey by SimplicityDX, 80% of respondents plan to use social media to find holiday gifts this year, with 41% planning to use it for most or all of their holiday shopping.

98

98

STAT

NOVEMBER 2, 2022

It’s tough times to be a public biotech, especially a small one. As the market cratered over the past year and a half, hundreds of companies watched their valuations plummet to the point that, at least by stock market metrics, they’re worth less than the cash they have in the bank. Now, one biotech investor is proposing a novel solution: Just give that cash back.

103

103

ISPE

NOVEMBER 2, 2022

2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. Trudy Patterson. Wed, 11/02/2022 - 07:32. iSpeak Blog. iSpeak. 2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. Susan Sandler. 2 November 2022. The industry is in the process of a transformation that was sped up by the pandemic, which enhanced innovation and collaboration.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

STAT

NOVEMBER 2, 2022

In the future, getting a flu shot might be as easy as opening the mailbox and slapping a skin patch on your arm. Immunizations shipped to doorsteps around the globe is the dream of Michael Schrader, chief executive and cofounder of Vaxess. For more than a decade, the Cambridge, Mass., startup — whose name is a portmanteau of “vaccine” and “access” — has inched toward the creation of a vaccine that’s easy to use, doesn’t require refrigeratio

Vaccines 103

Vaccines Immunization 103

PharmaVoice

NOVEMBER 2, 2022

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

Communication 98

Communication 98

STAT

NOVEMBER 2, 2022

A new British study suggests people who are infected with monkeypox may be able to transmit the virus to others before they develop noticeable symptoms of the disease — and that this type of transmission could account for a sizable portion of infections in the current international outbreak. Experts who reviewed the new analysis, published Wednesday in the journal BMJ, praised the rigor of the work, but warned that it cannot be considered the final answer on whether pre-symptomatic t

98

98

pharmaphorum

NOVEMBER 2, 2022

CVS Health and Walgreens have become the first two US pharmacy chains to agree a settlement worth nearly $10 billion to answer allegations they played a role in the opioid epidemic that has claimed tens of thousands of lives. CVS and Walgreens both said that the agreements in principle could resolve all the opioid-related lawsuits they are facing from states, subdivisions and Native American tribes.

Immunization 98

Immunization 98

STAT

NOVEMBER 2, 2022

The two largest U.S. pharmacy chains, CVS Health and Walgreen Co., announced agreements in principle Wednesday to pay about $5 billion each to settle lawsuits nationwide over the  toll of opioids , and a lawyer said Walmart, a third pharmacy behemoth, is in discussions for a deal. The prospective settlements are part of a shift in the legal landscape surrounding the opioid epidemic.

98

98

pharmaphorum

NOVEMBER 2, 2022

In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts’ estimates, with a healthy rise in revenue and profit driven by shingles vaccine Shingrix. The UK pharma group – now a therapeutics and vaccines pure-play since the spin-off of Haleon in July – also raised its financial forecasts for the full year for the second time in consecutive quarters, as third-quarter revenues climbed 18% to £7.8 billion (around $8.9 billion) against

Vaccines 97

Vaccines FDA 97

STAT

NOVEMBER 2, 2022

As states begin to receive money from the multitude of lawsuits and settlements the opioid makers and distributors have agreed to pay, the number of overdose deaths in the country continue to increase, reaching an all-time high in 2021. Researcher Linda Richter worries that not enough of the settlement funds, upward of $22 billion, are going toward early-stage prevention measures.

98

98

pharmaphorum

NOVEMBER 2, 2022

Wednesday 2 nd November heralds the start of Anthropy 2022 at The Eden Project. With pharmaphorum fully in attendance today, expect coverage of a wide range of topics, within a variety of formats, all united by a shared goal of seeking sustainable change for Britain, whilst bearing in mind her role upon the global stage at this critical juncture in history.

97

97

STAT

NOVEMBER 2, 2022

Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m picking up the baton from Drew as we continue to fill in for Ed this week. To kickstart my morning, I’ve poured myself a cup of some of the strongest stuff around — dihydrogen monoxide, 200 proof. Hope you remember your high school chemistry, and that you enjoy these newsy items as you start your Wednesday.

FDA 97

FDA Labelling 97

PharmaVoice

NOVEMBER 2, 2022

Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.

97

97

STAT

NOVEMBER 2, 2022

Hospitals that decide to convert to a new type of rural provider won’t have to report quality metrics next year, but they also won’t qualify for a popular drug discount program — a likely dealbreaker for some. That’s according to Medicare’s final rule laying out the parameters for so-called Rural Emergency Hospitals, a designation that takes effect Jan. 1, 2023 for facilities that opt in.

Hospitals 100

Hospitals 100